CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
驱动 CAR-T 细胞对抗实体瘤
英文原题：Driving CAR T Cells against Solid Tumors.
查看英文原题
Driving CAR T Cells against Solid Tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在 2022 年美国癌症研究协会（AACR）年会上，研究人员讨论了提高CAR-T 细胞疗法治疗实体瘤疗效的方法，包括厘清实体瘤与血液肿瘤对 CAR-T 细胞细胞毒作用的敏感性差异、采用模块化策略设计下一代治疗药物，以及为易耗竭的 CAR-T 细胞设置“休整机制”以恢复其功能。
展开英文摘要原文
During the American Association for Cancer Research Annual Meeting 2022, researchers discussed ways to improve chimeric antigen receptor T-cell therapy's efficacy in solid tumors. These included sussing out differences between solid and blood cancers in their susceptibility to CAR T cells' cytotoxicity, taking a modular approach to engineering next-generation agents, and building in breaks for exhaustion-prone CAR T cells to restore their function.
论文信息
- 期刊
- Cancer discovery2022 Jul 6
- 原文标识
- PubMed 35485880 · DOI 10.1158/2159-8290.CD-ND2022-0006